Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region

• Conditions: Pancreatic Neuroendocrine Tumor

• Registration Number: NCT04134832
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Pancreatic Neuroendocrine tumors and carcinomas (pNET) see the last year their incidence and prevalence going up. On the basis of their grade of differentiation and proliferation ratio measured Ki67 staining, there are divided into 3 grade groups : Grade 1 with Ki67 between 1 and 3%, Grade 2 between 3 and 20% and well-differentiated neuroendocrine grade tumors 3 with KI67 greater than 20%, so undifferentiated carcinomas.

pNET is a heterogenous group of tumors with variable prognosis. The aim of this study is to identify the prognostic factors in this population, as well the place of neutrophil-to-lymphocyte ratio as a prognostic marker. The primary endpoint is the description of clinic and pathological parameters of patients from Alsace. The secondary endpoints are the identification of prognostic factors in this population

Detailed Description

Not available

Study Timeline

• Study Start: 2019-06-27
• Status Verified: 2019-10
• Study First Submitted: 2019-10-18
• Study First Submitted QC: 2019-10-18
• Last Update Submitted: 2019-10-18
• Study First Posted: 2019-10-22
• Last Update Posted: 2019-10-22
• Primary Completion: 2020-06
• Study Completion: 2020-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The survival will be evaluated by Kaplan Meier Method. The prognostic factors will be evaluated with univariate and multivariate analysis by Cox regression model.	The participant will be followed-up for a maximum of 11 years, and 1 year at least.

Trial Locations

Locations (1)

Service D'Hematologie Et D'Oncologie; 🇫🇷 Strasbourg, France